[HTML][HTML] Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
G Shen, F Zheng, D Ren, F Du, Q Dong, Z Wang… - Journal of hematology & …, 2018 - Springer
Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular
endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet …
endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet …
Anlotinib: first global approval
YY Syed - Drugs, 2018 - Springer
Abstract Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Laboratories are co-
developing anlotinib (Focus V®) for the treatment of advanced cancer. Anlotinib is an oral …
developing anlotinib (Focus V®) for the treatment of advanced cancer. Anlotinib is an oral …
Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 randomized …
B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang… - JAMA …, 2018 - jamanetwork.com
Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …
[HTML][HTML] Emerging therapies for non-small cell lung cancer
Recent advances in the field of novel anticancer agents prolong patients' survival and show
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …
[HTML][HTML] Anlotinib: a novel targeted drug for bone and soft tissue sarcoma
S Li - Frontiers in oncology, 2021 - frontiersin.org
Bone and soft tissue sarcomas account for approximately 15% of pediatric solid malignant
tumors and 1% of adult solid malignant tumors. There are over 50 subtypes of sarcomas …
tumors and 1% of adult solid malignant tumors. There are over 50 subtypes of sarcomas …
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non‐small cell lung cancer after two lines of chemotherapy
M Zhou, X Chen, H Zhang, L Xia, X Tong… - Cancer …, 2019 - Wiley Online Library
Abstract Background On May 8, 2018, the China National Medical Products Administration
(NMPA) approved anlotinib, an orally administered anti‐angiogenesis inhibitor, for the …
(NMPA) approved anlotinib, an orally administered anti‐angiogenesis inhibitor, for the …
Anlotinib monotherapy for refractory metastatic colorectal cancer: A double-blinded, placebo-controlled, randomized phase III trial (ALTER0703)
Y Chi, Y Shu, Y Ba, Y Bai, B Qin, X Wang… - The …, 2021 - academic.oup.com
Background Treatment options for refractory metastatic colorectal cancer (mCRC) were
limited. Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was …
limited. Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was …
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
X Zhang, L Zeng, Y Li, Q Xu, H Yang, A Lizaso… - Cancer Immunology …, 2021 - Springer
Background This study evaluated the efficacy and safety of anlotinib combined with
programmed cell death protein 1 (PD-1) blockade for the treatment of small-cell lung cancer …
programmed cell death protein 1 (PD-1) blockade for the treatment of small-cell lung cancer …
[HTML][HTML] Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)
Y Sun, A Zhou, W Zhang, Z Jiang, B Chen, J Zhao… - Hepatology …, 2021 - Springer
Purpose This study aimed to assess efficacy and safety of anlotinib as a first-or second-line
treatment for advanced or metastatic hepatocellular carcinoma (aHCC) and to identify the …
treatment for advanced or metastatic hepatocellular carcinoma (aHCC) and to identify the …
[HTML][HTML] Anlotinib inhibits PFKFB3-driven glycolysis in myofibroblasts to reverse pulmonary fibrosis
W Chen, J Zhang, W Zhong, Y Liu, Y Lu… - Frontiers in …, 2021 - frontiersin.org
Idiopathic pulmonary fibrosis (IPF) is a fatal disease in which the normal alveolar network is
gradually replaced by fibrotic scars. Current evidence suggests that metabolic alterations …
gradually replaced by fibrotic scars. Current evidence suggests that metabolic alterations …